Technical Analysis for CCCC - C4 Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 0.00% | |
20 DMA Resistance | Bearish | 4.98% | |
Volume Surge | Other | 4.98% | |
20 DMA Resistance | Bearish | 4.98% | |
1,2,3 Retracement Bearish | Bearish Swing Setup | 4.98% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 4.98% | |
Inside Day | Range Contraction | 4.98% | |
Fell Below 20 DMA | Bearish | 4.75% | |
Doji - Bearish? | Reversal | 4.75% | |
Outside Day | Range Expansion | 4.75% |
Alert | Time |
---|---|
Up 3% | about 9 hours ago |
60 Minute Opening Range Breakout | about 9 hours ago |
Up 2% | about 9 hours ago |
Rose Above Previous Day's High | about 10 hours ago |
Rose Above 20 DMA | about 10 hours ago |
Get a Trading Sidekick!
- Earnings date: 08/06/2024
C4 Therapeutics, Inc. Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Treatment Of Cancer Non Small Cell Lung Cancer Melanoma Colorectal Cancer Multiple Myeloma NSCLC Synovial Sarcoma Treatment Of Various Cancers Peripheral T Cell Lymphoma
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 11.88 |
52 Week Low | 1.06 |
Average Volume | 1,634,231 |
200-Day Moving Average | 5.11 |
50-Day Moving Average | 5.51 |
20-Day Moving Average | 4.63 |
10-Day Moving Average | 4.47 |
Average True Range | 0.32 |
RSI (14) | 48.19 |
ADX | 40.49 |
+DI | 20.50 |
-DI | 30.04 |
Chandelier Exit (Long, 3 ATRs) | 4.24 |
Chandelier Exit (Short, 3 ATRs) | 4.86 |
Upper Bollinger Bands | 5.20 |
Lower Bollinger Band | 4.06 |
Percent B (%b) | 0.7 |
BandWidth | 24.55 |
MACD Line | -0.26 |
MACD Signal Line | -0.37 |
MACD Histogram | 0.1053 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 5.33 | ||||
Resistance 3 (R3) | 5.28 | 5.08 | 5.25 | ||
Resistance 2 (R2) | 5.08 | 4.95 | 5.10 | 5.22 | |
Resistance 1 (R1) | 4.96 | 4.88 | 5.02 | 5.01 | 5.19 |
Pivot Point | 4.76 | 4.76 | 4.79 | 4.78 | 4.76 |
Support 1 (S1) | 4.64 | 4.64 | 4.70 | 4.69 | 4.51 |
Support 2 (S2) | 4.44 | 4.56 | 4.46 | 4.48 | |
Support 3 (S3) | 4.33 | 4.44 | 4.45 | ||
Support 4 (S4) | 4.37 |